Aridis Pharmaceuticals, Inc.
ARDS · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $1,000 | $1,022 |
| % Growth | – | -100% | -2.2% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $1,000 | $1,022 |
| % Margin | – | – | 100% | 100% |
| R&D Expenses | $25,923 | $37,936 | $16,956 | $24,083 |
| G&A Expenses | $7,161 | $7,310 | $6,445 | $6,026 |
| SG&A Expenses | $7,161 | $7,310 | $6,445 | $6,026 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$3,091 | -$1,535 | $0 | $0 |
| Operating Expenses | $29,993 | $43,711 | $23,401 | $30,109 |
| Operating Income | -$29,993 | -$43,711 | -$22,401 | -$29,087 |
| % Margin | – | – | -2,240.1% | -2,846.1% |
| Other Income/Exp. Net | -$378 | $0 | $68 | -$594 |
| Pre-Tax Income | -$30,371 | -$43,193 | -$22,333 | -$29,681 |
| Tax Expense | $378 | -$912 | $0 | $0 |
| Net Income | -$30,749 | -$42,281 | -$22,333 | -$29,681 |
| % Margin | – | – | -2,233.3% | -2,904.2% |
| EPS | -1.64 | -3.44 | -2.44 | -3.43 |
| % Growth | 52.3% | -41% | 28.9% | – |
| EPS Diluted | -1.64 | -3.44 | -2.44 | -3.43 |
| Weighted Avg Shares Out | 18,777 | 12,292 | 9,169 | 8,458 |
| Weighted Avg Shares Out Dil | 18,777 | 12,292 | 9,169 | 8,458 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $77 | $357 |
| Interest Expense | $378 | -$245 | $0 | $0 |
| Depreciation & Amortization | $487 | -$722 | $337 | $338 |
| EBITDA | -$29,506 | -$44,433 | -$22,064 | -$28,749 |
| % Margin | – | – | -2,206.4% | -2,813% |